The Sidney Kimmel Comprehensive Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome
- Conditions
- LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
MS-275 in Treating Patients With Hematologic Cancer
- Conditions
- LeukemiaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer
- Conditions
- LeukemiaLymphomaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
- Conditions
- LeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
- Conditions
- Brain and Central Nervous System Tumors
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
CCI-779 in Treating Patients With Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-06-26
- Target Recruit Count
- 49
- Registration Number
- NCT00022724
- Locations
- 🇺🇸
Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus
- Conditions
- Esophageal Cancer
- Locations
- 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
- Conditions
- LymphomaSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-01-11
- Target Recruit Count
- 34
- Registration Number
- NCT00005639
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States